Lilly

Lilly discontinues 1 of 3 phase III rheumatoid arthritis registration studies for tabalumab

Friday, December 14, 2012 11:40 AM

Global pharmaceutical company Eli Lilly is halting one of three phase III rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy.

More... »

Janssen R&D establishes global cross-pharma clinical trial Investigator Databank

Monday, November 19, 2012 10:18 AM

Janssen Research & Development, based in Raritan, N.J., has established a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly are the first two companies to join Janssen in this effort.

More... »

Lilly to expand Indianapolis insulin manufacturing operations

Friday, November 2, 2012 10:38 AM

Global pharmaceutical company Eli Lilly announced a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000-square-foot expansion, which will enable the manufacturing of insulin cartridges to meet the growing diabetes demand in the U.S., represents one of the most significant investments in Lilly's U.S.-based manufacturing operations in the past decade.

More... »

Lilly touts positive results from phase III trials of dulaglutide in T2D

Monday, October 22, 2012 01:24 PM

Global pharmaceutical company Eli Lilly released positive top-line results of three completed phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes.

More... »

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »

Clinical research sites honor Eli Lilly, Medpace with Eagle Awards

Monday, October 15, 2012 11:57 AM

The 2012 Eagle Awards, presented to the top sponsor and top CRO as voted by clinical research sites, honored Eli Lilly and Medpace on Saturday, Oct. 13, at the annual Site Solutions Summit.

More... »

Investigational drugs chosen for major Alzheimer's prevention trial

Thursday, October 11, 2012 07:00 AM

Scientists have selected the first investigational drugs for a worldwide Alzheimer's disease prevention trial. The pioneering study, expected to start by early 2013, initially will test three promising drugs—gantenerumab, solanezumab and an unnamed BACE inhibitor—each designed to target Alzheimer's in different ways.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Lilly pomaglumetad methionil study falls short of primary endpoint

Thursday, July 12, 2012 04:35 PM

Eli Lilly reported negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of acute exacerbation of schizophrenia.

More... »